Search results

Technologies 26

View all

• FeCILL: Targeted Treatment for Severe Fungal Infections
  FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections.
• Ichor: Reversing Aging
  Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health.
• Sugar-to-Fiber Enzyme for Healthier Food
  In collaboration with Kraft Heinz, our sugar-to-fiber product can convert sugar in food products into prebiotic fiber in the human gut, reducing the amount of sugar absorbed into the bloodstream without altering the amount of sugar in existing food product recipes.
• eRapid: Multiplexed Electrochemical Detection of Complex Diseases
  StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders.
• CogniXense for Rare Disease Drug Discovery
  Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.
• Molecular Nucleic Acid Detection Technology to Empower Patients with Self-Testing Capabilities
  This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute, then transformed into an inexpensive, reliable and manufacturable detection system by 3EO Health.

Collaborations 2

• Kraft Heinz Partnership
  The Kraft Heinz company approached the Wyss Institute for help to achieve its ambitious goal to make its food products healthier, resulting in a novel technology that is ripe for commercialization.
• Brain Targeting Program
  Pre-competitive multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain.

News 231

View all

• Press Release
  
  Not all statins are created equal
  May 9, 2023
• Press Release
  
  A backpack full of multiple sclerosis therapy
  April 21, 2023
• Press Release
  
  Wyss Diagnostics Accelerator’s Industrial Participant Program goes official
  April 13, 2023

Multimedia 74

View all

• 

  Video/Animation
  How can we get diagnostics to patients faster?
  The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  How can we feed the world?
  The current agricultural methods of feeding the world are not sustainable and already have dire consequences that will worsen as the Earth’s population continues to grow. Researchers at the Wyss Institute are working on various solutions that could help provide food for our future needs with a lower environmental impact. Credit: Wyss Institute at Harvard...

• 

  Video/Animation
  How can we better treat brain diseases?
  The Brain Targeting Program at the Wyss Institute is a pre-competitive, multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  Wyss Diagnostics Accelerator – The Industrial Participant Program
  The Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  FeCILL: Reimagining How We Treat the Sickest Patients
  Opportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute...

• 

  Video/Animation
  Reimagining Protein Engineering Inspired by His Father: Mike Super
  Mike Super is a Lead Staff Scientist using protein engineering to design therapeutic and diagnostic devices to treat cancer, and infectious and immunological diseases. He also leads the Biostasis team at the Wyss. In this video, he shares his personal and professional journey that began in the deserts of Namibia shadowing his father, one of...